Press release
Myocardial Infarction Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Pfizer, Novartis, AstraZeneca, Recardio, Idorsia Pharma, Eli Lilly and Company
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Myocardial Infarction Market Report:
* The Myocardial Infarction market size was valued approximately USD 21 Billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In the 7MM, the United States had the highest number of diagnosed prevalent cases. The total diagnosed prevalent cases of myocardial infarction (MI) in the US were approximately 8,038,230 in 2021.
* In November 2022, During the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions, Amgen disclosed end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran. These results were also simultaneously published in the New England Journal of Medicine
* The data readouts from the Phase III (DAPA-MI) study of FARXIGA/FORXIGA are anticipated by 2H 2023, according to AstraZeneca's Q32022 investor presentation. an important regulatory submission estimated to be accepted after 2023
* For the age group >35 years from 2015 to 2035, Kuhn et al. (2022) assessed the prevalence of MI in both men and women. According to the report, there were 519,400 Myocardial Infarction patients hospitalised in France between 2007 and 2015, with a higher percentage of men than women. Men's and women's average ages were 65.0 and 74.9 respectively; 45.8% of Myocardial Infarction hospitalised men were aged 55 to 74
* Germany had the most diagnosed prevalent MI cases among the EU4 nations, whereas Spain had the lowest prevalence rate among the 7MM
* According to Kuhn et al. (2022), the prevalence of myocardial infarction (MI) in individuals over the age of 35 was estimated from 2015 to 2035 for both men and women. From 2007 to 2015, 519,400 patients in France were hospitalized for MI, with a higher percentage being men. The average age was 65.0 for men and 74.9 for women, and nearly half of the men hospitalized for MI (45.8%) fell within the age range of 55 to 74.
* Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
* Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal Registered , Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others
* The Myocardial Infarction epidemiology based on gender analyzed that the prevalence of myocardial infarction (MI) is more common among males as compared to females
* The Myocardial Infarction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myocardial Infarction pipeline products will significantly revolutionize the Myocardial Infarction market dynamics.
Myocardial Infarction Overview
Myocardial infarction, commonly known as a heart attack, occurs when the blood flow to a part of the heart muscle is blocked for an extended period. This blockage typically happens due to the rupture of a plaque buildup in one of the coronary arteries, which supply oxygen-rich blood to the heart muscle. Without adequate blood flow, the affected portion of the heart muscle begins to die.
Get a Free sample for the Myocardial Infarction Market Report:
https://www.delveinsight.com/report-store/myocardial-infarction-market [https://www.delveinsight.com/report-store/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Myocardial Infarction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Myocardial Infarction Epidemiology Segmentation:
The Myocardial Infarction market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Prevalence of Myocardial Infarction
* Prevalent Cases of Myocardial Infarction by severity
* Gender-specific Prevalence of Myocardial Infarction
* Diagnosed Cases of Episodic and Chronic Myocardial Infarction
Download the report to understand which factors are driving Myocardial Infarction epidemiology trends @ Myocardial Infarction Epidemiology Forecast [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Myocardial Infarction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myocardial Infarction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Myocardial Infarction Therapies and Key Companies
* JARDIANCE (empagliflozin): Boehringer Ingelheim/ Eli Lilly
* Pelacarsen: Novartis
* FARXIGA(dapagliflozin): AstraZeneca
* Dutogliptin: Recardio
* Selatogrel: Idorsia Pharmaceuticals
* abciximab: Eli Lilly and Company
* Empagliflozin: Boehringer Ingelheim
* Aliskiren: Novartis
* Eplerenone: Pfizer
* Fulacimstat (BAY1142524): Bayer
* Prochymal Registered : Mesoblast, Inc.
* Angiomax (bivalirudin) anticoagulant: The Medicines Company
* TNK-tPA: Boehringer Ingelheim
* MCC-135: Mitsubishi Tanabe Pharma
* ATH3G10: Athera Biotechnologies
* RO4905417: Hoffmann-La Roche
* Selatogrel: Idorsia Pharmaceuticals, and others
Discover more about therapies set to grab major Myocardial Infarction market share @ Myocardial Infarction Treatment Market [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Myocardial Infarction Market Strengths
* Increasing focus on the secondary preventive measure to avoid recurrent/new events, and lifestyle changes, along with the growing number of smokers and increasing cases of obesity, diabetes, hypertension, and others, are expected to foster the market growth of Myocardial Infarction
Myocardial Infarction Market Opportunities
* Major cost drivers in the 7MM healthcare system are heart attacks and strokes. The volume of the MI market is incredibly large. The patient receives several therapies concurrently. The smallest patient share portion can provide pharmaceutical companies with options worth millions of dollars
Scope of the Myocardial Infarction Market Report
* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
* Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal Registered , Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others
* Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies
* Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Myocardial Infarction Unmet Needs, KOL's views, Analyst's views, Myocardial Infarction Market Access and Reimbursement
To know more about Myocardial Infarction companies working in the treatment market, visit @ Myocardial Infarction Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Myocardial Infarction Market Report Introduction
2. Executive Summary for Myocardial Infarction
3. SWOT analysis of Myocardial Infarction
4. Myocardial Infarction Patient Share (%) Overview at a Glance
5. Myocardial Infarction Market Overview at a Glance
6. Myocardial Infarction Disease Background and Overview
7. Myocardial Infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Myocardial Infarction
9. Myocardial Infarction Current Treatment and Medical Practices
10. Myocardial Infarction Unmet Needs
11. Myocardial Infarction Emerging Therapies
12. Myocardial Infarction Market Outlook
13. Country-Wise Myocardial Infarction Market Analysis (2019-2032)
14. Myocardial Infarction Market Access and Reimbursement of Therapies
15. Myocardial Infarction Market Drivers
16. Myocardial Infarction Market Barriers
17. Myocardial Infarction Appendix
18. Myocardial Infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myocardial-infarction-market-to-witness-upsurge-in-growth-during-the-forecast-period-20232032-examine-delveinsight-pfizer-novartis-astrazeneca-recardio-idorsia-pharma-eli-lilly-and-company]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myocardial Infarction Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Pfizer, Novartis, AstraZeneca, Recardio, Idorsia Pharma, Eli Lilly and Company here
News-ID: 3475360 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Myocardial
Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Numb …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual…
Diabetes Epidemic Fuels Myocardial Ischemia Market Growth: An Emerging Driver Tr …
The Myocardial Ischemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Myocardial Ischemia Market?
The myocardial ischemia market has grown strongly. It will grow from $0.79 billion in 2024 to $0.85 billion in 2025 at a CAGR of 7.3%.…
Transforming the Myocardial Ischemia Market in 2025: Diabetes Epidemic Fuels Myo …
What Is the Expected Size and Growth Rate of the Myocardial Ischemia Market?
The market size for myocardial ischemia has demonstrated considerable growth over the last few years. There's a predicted growth from $0.79 billion in 2024 to $0.85 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial growth during the historical period can be credited to the use of telemedicine and remote monitoring, the discovery…
Myocardial Infarction Treatment Market Growth and Insights 2024
"The Business Research Company recently released a comprehensive report on the Global Myocardial Infarction Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Myocardial Infarction Drugs Market
According to a new report published by Allied Market Research, titled, "Myocardial Infarction Drugs Market by Product Type (Analgesics, Antiplatelet Agents, Vasodilators, Thrombolytics, Anti-Thrombotic Agents, Glycoprotein IIb/IIIa Inhibitors, Î' Adrenergic Blockers, Angiotensin Receptor Blockers, and Angiotensin Converting Enzyme Inhibitors) and by Distribution Channel (Hospital Pharmacies, Hospitals, Drug Stores, and Online Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2019-2026".
The Global market size of Myocardial Infarction Drugs Market was $XX…
Myocardial Ischemia - Pipeline Review, H1 2017 - Pharmaceutical Report
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, clammy skin, shortness of breath and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm…
